Spravato
Spravato for Treatment-Resistant Depression (TRD)
Is your depression not responding to medication and therapy? Consider Spravato at Conventions Psychiatry and Counseling in Warrenville, IL. Spravato is an FDA-approved nasal spray for treatment-resistant depression, used in conjunction with your current oral antidepressants. Proven effective for adults with Major Depressive Disorder (MDD) who have not seen improvement with at least two medications, Spravato is administered twice weekly.
Schedule a consultation with Michelle dela Peña to discuss expectations, benefits, and risks, and explore whether Spravato treatment is right for you.
Spravato Treatments In Warrenville
While Spravato is self-administered, patients are required to come in to our office, at prescribed frequency to self administer under staff supervision . Patients must be also be monitored in office for two hours after each administration. This is to ensure safety and allow our certified medical professionals to monitor and assist with any side effects that may occur.
Understanding SPRAVATO At Conventions Psychiatry & Counseling/ Conventions health:
A Comprehensive Guide for Patients
Introduction
In recent years, the landscape of mental health treatment has evolved significantly, particularly in the realm of depression management. Among the innovative therapies available, SPRAVATO® (
What is SPRAVATO?
SPRAVATO is an FDA-approved nasal spray specifically designed for adults diagnosed with treatment-resistant depression. It is also indicated for the management of depressive symptoms in adults with major depressive disorder (MDD) when traditional oral antidepressants have proven ineffective. SPRAVATO is unique in its formulation, as it is derived from esketamine, a compound that acts on the brain’s neurotransmitter systems.
Mechanism of Action
The primary mechanism by which SPRAVATO operates involves the modulation of the glutamatergic system. Unlike conventional antidepressants that primarily target serotonin or norepinephrine, SPRAVATO works by blocking the N-methyl-D-aspartate (NMDA) receptor, which is believed to play a crucial role in mood regulation. This action leads to a rapid reduction in depressive symptoms, often within hours of administration, making it a significant advancement in the treatment of depression.
Administration of SPRAVATO
SPRAVATO is administered as a nasal spray under the supervision of a healthcare professional. The treatment protocol typically involves the following steps:
- Initial Assessment: Patients undergo a thorough evaluation to determine their suitability for SPRAVATO, including a review of their medical history and previous treatment responses.
- Dosing Schedule: The initial dosing schedule generally consists of two treatments per week for the first four weeks. Following this period, the frequency may be adjusted based on the patient’s response and clinical judgment.
- Monitoring: After administration, patients are required to remain at the healthcare facility for at least two hours for monitoring due to the potential for side effects, including sedation and dissociation.
Considerations for Patients
Before initiating treatment with SPRAVATO, patients should consider the following:
- Medical History: Inform your healthcare provider of any pre-existing conditions, particularly those related to cardiovascular health, as SPRAVATO can elevate blood pressure.
- Substance Use: Patients with a history of substance use disorders should discuss this with their provider, as SPRAVATO has the potential for abuse.
- Pregnancy and Breastfeeding: Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider to weigh the risks and benefits of SPRAVATO.
Side Effects
- Sedation
- Dissociation
- Nausea
- Increased blood pressure
Patients must be driven home after each treatment by a friend or family member.
Spravato is not to be used in those with a history of bleeding in the brain, aneurysm, arteriovenous malformation, substance abuse, or pregnancy, or psychosis.